Prostaglandin G/H synthase 2
Also known as: COX2, PTGS2
Function
Dual cyclooxygenase and peroxidase in the biosynthesis pathway of prostanoids, a class of C20 oxylipins mainly derived from arachidonate ((5Z,8Z,11Z,14Z)-eicosatetraenoate, AA, C20:4(n-6)), with a particular role in the inflammatory response. The cyclooxygenase activity oxygenates AA to the hydroperoxy endoperoxide prostaglandin G2 (PGG2), and the peroxidase activity reduces PGG2 to the hydroxy endoperoxide prostaglandin H2 (PGH2), the precursor of all 2-series prostaglandins and thromboxanes. This complex transformation is initiated by abstraction of hydrogen at carbon 13 (with S-stereochemistry), followed by insertion of molecular O2 to form the endoperoxide bridge between carbon 9 and 11 that defines prostaglandins. The insertion of a second molecule of O2 (bis-oxygenase activity) yields a hydroperoxy group in PGG2 that is then reduced to PGH2 by two electrons. Similarly catalyzes successive cyclooxygenation and peroxidation of dihomo-gamma-linoleate (DGLA, C20:3(n-6)) and eicosapentaenoate (EPA, C20:5(n-3)) to corresponding PGH1 and PGH3, the precursors of 1- and 3-series prostaglandins. In an alternative pathway of prostanoid biosynthesis, converts 2-arachidonoyl lysophopholipids to prostanoid lysophopholipids, which are then hydrolyzed by intracellular phospholipases to release free prostanoids. Metabolizes 2-arachidonoyl glycerol yielding the glyceryl ester of PGH2, a process that can contribute to pain response. Generates lipid mediators from n-3 and n-6 polyunsaturated fatty acids (PUFAs) via a lipoxygenase-type mechanism. Oxygenates PUFAs to hydroperoxy compounds and then reduces them to corresponding alcohols. Plays a role in the generation of resolution phase interaction products (resolvins) during both sterile and infectious inflammation. Metabolizes docosahexaenoate (DHA, C22:6(n-3)) to 17R-HDHA, a precursor of the D-series resolvins (RvDs). As a component of the biosynthetic pathway of E-series resolvins (RvEs), converts eicosapentaenoate (EPA, C20:5(n-3)) primarily to 18S-HEPE that is further metabolized by ALOX5 and LTA4H to generate 18S-RvE1 and 18S-RvE2. In vascular endothelial cells, converts docosapentaenoate (DPA, C22:5(n-3)) to 13R-HDPA, a precursor for 13-series resolvins (RvTs) shown to activate macrophage phagocytosis during bacterial infection. In activated leukocytes, contributes to oxygenation of hydroxyeicosatetraenoates (HETE) to diHETES (5,15-diHETE and 5,11-diHETE). Can also use linoleate (LA, (9Z,12Z)-octadecadienoate, C18:2(n-6)) as substrate and produce hydroxyoctadecadienoates (HODEs) in a regio- and stereospecific manner, being (9R)-HODE ((9R)-hydroxy-(10E,12Z)-octadecadienoate) and (13S)-HODE ((13S)-hydroxy-(9Z,11E)-octadecadienoate) its major products (By similarity). During neuroinflammation, plays a role in neuronal secretion of specialized preresolving mediators (SPMs) 15R-lipoxin A4 that regulates phagocytic microglia (By similarity).
Classification
- Family (Pfam)
- PF03098 An_peroxidase
- InterPro
- EGF, Haem_peroxidase_animal, Haem_peroxidase_sf, Haem_peroxidase_sf_animal, Oxylipin_biosynth_metab
- Functional cluster
- Oxidoreductases, Catalases & Peroxidases
Experimental structures · PDB · 7
- 5F19 X-ray 2.04A
- 5F1A X-ray 2.38A
- 5IKQ X-ray 2.41A
- 5IKR X-ray 2.34A
- 5IKT X-ray 2.45A
- 5IKV X-ray 2.51A
- 5KIR X-ray 2.70A
A predicted model is available from AlphaFold.
Gene Ontology · 36
- GO:0005737 cytoplasm
- GO:0005783 endoplasmic reticulum
- GO:0005788 endoplasmic reticulum lumen
- GO:0005789 endoplasmic reticulum membrane
- GO:0043005 neuron projection
- GO:0005637 nuclear inner membrane
- GO:0005640 nuclear outer membrane
- GO:0019899 enzyme binding
- GO:0020037 heme binding
- GO:0046872 metal ion binding
- GO:0016701 oxidoreductase activity, acting on single donors with incorporation of molecular oxygen
- GO:0016702 oxidoreductase activity, acting on single donors with incorporation of molecular oxygen, incorporation of two atoms of oxygen
- GO:0004601 peroxidase activity
- GO:0004666 prostaglandin-endoperoxide synthase activity
- GO:0042803 protein homodimerization activity
- GO:0050873 brown fat cell differentiation
- GO:0071456 cellular response to hypoxia
- GO:0071471 cellular response to non-ionic osmotic stress
- GO:0019371 cyclooxygenase pathway
- GO:0019372 lipoxygenase pathway
- GO:0042759 long-chain fatty acid biosynthetic process
- GO:1902219 negative regulation of intrinsic apoptotic signaling pathway in response to osmotic stress
- GO:0090336 positive regulation of brown fat cell differentiation
- GO:0090050 positive regulation of cell migration involved in sprouting angiogenesis
- GO:0031622 positive regulation of fever generation
- GO:0090271 positive regulation of fibroblast growth factor production
- GO:0045429 positive regulation of nitric oxide biosynthetic process
- GO:0090362 positive regulation of platelet-derived growth factor production
- GO:0031394 positive regulation of prostaglandin biosynthetic process
- GO:0071636 positive regulation of transforming growth factor beta production
- GO:0010575 positive regulation of vascular endothelial growth factor production
- GO:0001516 prostaglandin biosynthetic process
- GO:0008217 regulation of blood pressure
- GO:0050727 regulation of inflammatory response
- GO:0150077 regulation of neuroinflammatory response
- GO:0006979 response to oxidative stress
Drugs targeting this protein · 71
- PHENYLBUTAZONE inhibitor
- NEPAFENAC inhibitor
- DICLOFENAC SODIUM inhibitor
- NABUMETONE inhibitor
- OXAPROZIN inhibitor
- ACETAMINOPHEN inhibitor
- CELECOXIB inhibitor
- OXAPROZIN POTASSIUM inhibitor
- TOLMETIN SODIUM inhibitor
- BALSALAZIDE DISODIUM inhibitor
- DICLOFENAC POTASSIUM inhibitor
- NAPROXEN SODIUM inhibitor
- OLSALAZINE SODIUM inhibitor
- KETOROLAC TROMETHAMINE inhibitor
- IBUPROFEN LYSINE inhibitor
- DICLOFENAC EPOLAMINE inhibitor
- PARECOXIB inhibitor
- ROFECOXIB inhibitor
- BENZYDAMINE inhibitor
- CARPROFEN inhibitor
- CLOMETACIN inhibitor
- DICLOFENAC inhibitor
- GLAFENINE inhibitor
- BENZYDAMINE HYDROCHLORIDE inhibitor
- NAPROXEN inhibitor
- MECLOFENAMATE SODIUM inhibitor
- APAZONE inhibitor
- FENCLOFENAC inhibitor
- LORNOXICAM inhibitor
- SULINDAC inhibitor
- INDOPROFEN inhibitor
- POLMACOXIB inhibitor
- DEXIBUPROFEN inhibitor
- APRICOXIB inhibitor
- PIRPROFEN inhibitor
- ACEMETACIN inhibitor
- LOXOPROFEN inhibitor
- FENOPROFEN CALCIUM inhibitor
- NAPROXCINOD inhibitor
- NAPROXEN ETEMESIL inhibitor
- IGURATIMOD inhibitor
- ASPIRIN inhibitor
- PARECOXIB SODIUM inhibitor
- BROMFENAC SODIUM inhibitor
- IBUFENAC inhibitor
- GW-406381 inhibitor
- IBUPROFEN SODIUM inhibitor
- INDOMETHACIN SODIUM inhibitor
- OXYPHENBUTAZONE inhibitor
- FLURBIPROFEN SODIUM inhibitor
- DIPYRONE inhibitor
- LUMIRACOXIB inhibitor
- ETORICOXIB inhibitor
- SULFASALAZINE inhibitor
- ESFLURBIPROFEN inhibitor
- CIMICOXIB inhibitor
- IBUPROFEN inhibitor
- PIROXICAM inhibitor
- ISOXICAM inhibitor
- FLURBIPROFEN inhibitor
- KETOPROFEN inhibitor
- MELOXICAM inhibitor
- INDOMETHACIN inhibitor
- ETODOLAC inhibitor
- MEFENAMIC ACID inhibitor
- MESALAMINE inhibitor
- DEXKETOPROFEN inhibitor
- VALDECOXIB inhibitor
- DIFLUNISAL inhibitor
- ACECLOFENAC inhibitor
- SUPROFEN inhibitor
Related proteins · sequence + function similarity
- Prostaglandin G/H synthase 2 0.99
- Prostaglandin G/H synthase 2 0.99
- Prostaglandin G/H synthase 2 0.99
- Prostaglandin G/H synthase 2 0.99
- Prostaglandin G/H synthase 2 0.99
- Prostaglandin G/H synthase 2 0.99
- Prostaglandin G/H synthase 2 0.99
- Prostaglandin G/H synthase 2 0.98
- Prostaglandin G/H synthase 2 0.98
- Prostaglandin G/H synthase 1 0.96
- Prostaglandin G/H synthase 1 0.95
- Prostaglandin G/H synthase 1 0.95
Co-cited proteins · studied together in the literature
- Prostaglandin G/H synthase 2 4 shared papers
- Prostaglandin G/H synthase 1 4 shared papers
- Cytosolic phospholipase A2 1 shared papers
- Nitric oxide synthase, inducible 1 shared papers
- Leukotriene A-4 hydrolase 1 shared papers
- Polyunsaturated fatty acid 5-lipoxygenase 2 shared papers
- Prostaglandin G/H synthase 2 2 shared papers
- Prostaglandin G/H synthase 1 2 shared papers
- Prostaglandin G/H synthase 1 1 shared papers
- Prostaglandin G/H synthase 1 2 shared papers
- Polyunsaturated fatty acid lipoxygenase ALOX12 1 shared papers
Literature · 31 cited papers
- Crystal structure of rofecoxib bound to human cyclooxygenase-2. Acta Crystallogr. F · 2016
- Cyclooxygenase-2 Mediated Oxidation of 2-Arachidonoyl-Lysophospholipids Identifies Unknown Lipid Signaling Pathways. Cell Chem. Biol. · 2016
- Substrate-selective Inhibition of Cyclooxygeanse-2 by Fenamic Acid Derivatives Is Dependent on Peroxide Tone. J. Biol. Chem. · 2016
- Crystal Structure of Aspirin-Acetylated Human Cyclooxygenase-2: Insight into the Formation of Products with Reversed Stereochemistry. Biochemistry · 2016
- Inhibition of long-chain acyl-CoA synthetase 4 facilitates production of 5, 11-dihydroxyeicosatetraenoic acid via the cyclooxygenase-2 pathway. Biochem. Biophys. Res. Commun. · 2015
- Elucidation of novel 13-series resolvins that increase with atorvastatin and clear infections. Nat. Med. · 2015
- Aspirin, cyclooxygenase inhibition and colorectal cancer. World J. Gastrointest. Pharmacol. Ther. · 2014
- Prostaglandin H synthase-2-catalyzed oxygenation of 2-arachidonoylglycerol is more sensitive to peroxide tone than oxygenation of arachidonic acid. J. Biol. Chem. · 2012
- COX-2-dependent and -independent biosynthesis of dihydroxy-arachidonic acids in activated human leukocytes. J. Lipid Res. · 2012
- Pro-resolving actions and stereoselective biosynthesis of 18S E-series resolvins in human leukocytes and murine inflammation. J. Clin. Invest. · 2011
- The essentiality of arachidonic acid and docosahexaenoic acid. Prostaglandins Leukot. Essent. Fatty Acids · 2009
- Glycosylation regulates turnover of cyclooxygenase-2. FEBS Lett. · 2006
- … and 19 more in the literature graph